LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET
Company Participants
David B. Roberts – President & Director
Dorian LeBlanc – Chief Financial Officer
George W. LeMaitre – Chairman & CEO
Conference Call Participants
Brett Adam Fishbin – KeyBanc Capital Markets Inc., Research Division
Daniel Walker Stauder – Citizens JMP Securities, LLC, Research Division
Frank James Takkinen – Lake Street Capital Markets, LLC, Research Division
Jason Hart Wittes – ROTH Capital Partners, LLC, Research Division
Michael Anthony Sarcone – Jefferies LLC, Research Division
Michael John Petusky – Barrington Research Associates, Inc., Research Division
Nathan Treybeck – Wells Fargo Securities, LLC, Research Division
Ross Everett Osborn – Cantor Fitzgerald & Co., Research Division
Suraj Kalia – Oppenheimer & Co. Inc., Research Division
Operator
Welcome to the LeMaitre Vascular Q2 2025 Fiscal Results Conference Call. As a reminder, today’s call is being recorded.
Dorian LeBlanc
At this time, I would like to turn the call over to Mr. Dorian LeBlance, Chief Financial Officer of LeMaitre Vascular. Please go ahead, sir. Thank you, operator. Good afternoon, and thank you for joining us on our Q2 2025 conference call. With me on today’s call is our CEO, George LeMaitre; and our President, Dave Roberts. Before we begin, I’ll read our safe harbor statement. Today, we’ll be making some forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, the accuracy of which is subject to risks and uncertainties. Wherever possible, we will try to identify those forward-looking statements by using words such as believe, expect, anticipate, pursue, forecast and similar expressions.
Our forward-looking statements are based on our estimates and assumptions as of today, August 5, 2025, and should not be relied upon as representing our estimates or views on any subsequent date. Please refer to the
